These results suggest that inhibiting HDAC might sensitize APL cells to ATRA, which would be critical for patients who carry other variants of 17q chromosome translocation, such as promyelocytic leukemia zinc finger protein PLZF-RAR-α [t(11;17)], or patients who relapse. This evidence concerns the gene RARA and acute promyelocytic leukemia.